Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy

Current Medical Research and Opinion

Volumn 24, Issue 9, 2008, Pages 2663-2667

  Motolko, Michael A ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Brimonidine; Fixed combination; Glaucoma; Ocular allergy; Timolol

Indexed keywords

ANTIGLAUCOMA AGENT; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; COMBIGAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EYE ALLERGY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PSEUDOEXFOLIATION; RISK REDUCTION; TREATMENT DURATION; TREND STUDY;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; CONJUNCTIVITIS, ALLERGIC; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA; HUMANS; MALE; MIDDLE AGED; QUINOXALINES; TIMOLOL;

EID: 53349109120     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802333167     Document Type: Article

References (18)

1. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol 2000;130:832-3
2. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230-8
3. Katz U. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999;127:20-6
4. Arici MK, Sayici M, Toker M, et al. A short term study of the additive effect of timolol and brimonidine on intraocular pressure. Eye 2002;16:39-43
5. Solish AM, DeLucca PT, Cassel DA, et al. Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004;13:149-57
6. Simmons ST, Earl ML. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology 2002;109:307-14
7. Goni FJ. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15:581-90
8. Alvarado JA. Reduced ocular allergy with fixed-combination 0.2% brimonidine-0.5% timolol. Arch Ophthalmol 2007; 125:717 [author reply 717-8]
9. Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye 2004;18:24-6
10. Becker HI, Walton RC, Diamant JI, et al. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Arch Ophthalmol 2004; 122:1063-6
11. Hegde V, Robinson R, Dean F, et al. Drug-induced ectropion: what is best practice? Ophthalmology 2007; 114:362-6
12. Spaeth GL. Allergic contact dermatitis caused by topical eye drops. Am J Ophthalmol 2006;142:706
13. Manni G, Centofanti M, Sacchetti M, et al. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. J Glaucoma 2004;13: 163-7
14. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11:119-26
15. Kim CY, Hong S, Seong GJ. Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther 2007;23:481-6
16. Osborne SA, Montgomery DM, Morris D, et al. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye 2005;19:129-37
17. Van Buskirk EM, Bacon DR, Fahrenbach WH. Ciliary vasoconstriction after topical adrenergic drugs. Am J Ophthalmol 1990; 109:511-7
18. Butler P, Mannschreck M, Lin S, et al. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol 1995;113:293-6